Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2014 Oct 16;10(1):35–44. doi: 10.1007/s11481-014-9568-7

Figure 6.

Figure 6

A. Densitometry against OX6 in the SN shows an increase in MHC-II immunoreactivity in LPSinfused rats treated with vehicle, which is significantly reduced in dantrolene and nimodipine treated LPS-infused rats, with a full recovery observed with nimodipine. B. Densitometry against OX6 in the LC shows an increase in MHC-II immunoreactivity in LPS-infused rats treated with vehicle or dantrolene, which is significantly reduced in nimodipine treated LPS-infused rats, indicating a full recovery. Data expressed as mean ± SEM. * indicates a significant difference from treatment-matched aCSF controls, †indicates a significant difference from LPS + vehicle rats. Significance set as p<0.05.